A recent study from Watson-Marlow Fluid Technology Group (WMFTG), demonstrates that PureWelda XL tubing offers extended lifespan and steady flow consistency when compared to other leading brands. Dr Chris Palmer, Tubing Product Manager at WMFTG, will share the results of the study at The Single Use Event, Antwerp on 10th September.
Continuous processing has the potential to significantly increase the efficiency of biologics manufacture, reducing production costs and the price of pharmaceuticals. In order to achieve this, all single-use components must be able to maintain integrity for extended production cycles of up to 90 days. Manufacturers must therefore consider the practical performance of every component when planning their production.
This study from WMFTG compares the peristaltic life and pumping performance of three SEBS Based thermoplastic elastomer (TPE) tubing products. PureWelda XL tubing demonstrated significantly longer peristaltic life and sustained pumping performance when compared with the two other leading brands. Dr Palmer will discuss the results at The Single Use Event and look deeper into the implications this has for drug manufacturers and process engineers in the future.
Dr Palmer commented, “This recent study confirms the need for drug manufacturers to consider the lifespan and quality of all components when designing a continuous bioprocessing system. WMFTG is always seeking to improve its offerings to satisfy future customer requirements across multiple industries, including biopharmaceutical manufacturing. The growing adoption of single-use technologies in bioprocessing has propelled tubing from a minor to a major component of the manufacturing process, and the results of these tests demonstrate the benefits of choosing PureWeld XL tubing for the production of new medicines.”
Don’t miss Dr Palmer’s talk at The Single Use Event, 13.30-13.55 on 10th September for the full results of the study.